Bangalore, Oct 7, 2008: According to a report jointly prepared by trade body Confederation of India Industries (CII) and consultancy firm KPMG, the Indian biotechnology sector is predicted to become a five billion-dollar industry by 2010.
"The Indian biotechnology sector has excellent potential and is expected to touch five billion-dollar mark by 2010. India is ranked among the top 12 biotech destinations in the world and is the third biggest in Asia-Pacific in terms of the number of biotech companies,” the report said.
According top the report, availability of talent pool in the country is a big advantage for the Indian companies. The sector employs about 20,000 scientists, with investments growing at the rate of about 38 percent for the last three years.
The report pointed out that educational infrastructure need to be upgraded to facilitate further progress in the industry. "India needs to invest in building a strong capability base in order to leverage large opportunities going forward. There are no shortcuts," said Kiran Mazumdar Shaw, CEO and MD, Biocon.
According to the report, Biopharma is one of the important segments of the Indian biotechnology sector and it constitutes about 70 percent of the domestic biotech industry.Of the total 325 biotechnology companies in India, more than 40 percent are in the biopharma sector, the report said.
Friday, October 17, 2008
Friday, September 19, 2008
Pharma Advertising
Marketing Mix of Leading Pharma Advertisers
Thirteen (13) pharmaceutical companies made it into AdAge's 2008 list of 100 National Advertisers. They are:
GlaxoSmithKline
Johnson & Johnson
Pfizer
Schering-Plough Corp.
Wyeth
Bayer
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Merck & Co.
AstraZeneca
Novartis
Boehringer Ingelheim
Sanofi-AventisThe list is based on "measured media" spending across 19 media and includes estimates of "unmeasured media," which includes direct marketing, product placement, and most notably, paid Internet search, which some analysts estimate is about 40% of the total ad spend of companies in general.New to the list this year is Boehringer Ingelheim, which markets Mirapex for Restless Leg Syndrome in competition with GSK's Requip.The total spend for these 13 pharma companies in 2007 was $6,998,700,000 measured vs. and estimated $6,834,600,000 unmeasured. That represents 13.1% of the total spending in 2007 of the entire group. NOTE: Not all of this represents direct-to-consumer (DTC) advertising. Magazines, for example, include B-2-B publications (ie, medical journals focused on physicians).I plotted the media mix for pharma advertisers vs. non-pharma companies in the list and came up with this (click on the image for a larger view):Based on these data, the top spending pharma companies have a media mix distinctly different from the top non-pharma companies. Pharma devotes a greater slice of its advertising pie to TV and magazines than do non-pharma companies. In fact, 92% of pharma's budget is devoted to these two categories of media! That leaves scant dollars for other media.It makes sense that pharma would not spend as large a portion of its ad budget on newspapers, radio, and outdoor venues. These media focus on local markets rather than mass markets and pharma has little need to tailor their messages to local markets (although some drug categories may benefit from more exposure in communities with disproportionate medical problems, such as diabetes in African-American neighborhoods).Why Pharma Lags in Internet AdvertisingBut it is surprising that pharmaceutical companies -- at least the 13 in this group of top spenders -- devotes only 3.1% of their ad budgets on the Internet whereas non-pharmaceutical companies devote 7.3% of their budgets to the Internet.Why is this?I believe that most pharmaceutical marketers have a mass-market mentality and do not view the Internet as a mass market medium. Every defense I've heard from these marketers for why they are not spending much on the Internet includes the phrase "lack of reach" in comparison to TV and magazines. True enough.Also, the Internet is not nearly as motivating as TV in getting consumers to visit their doctors and ask for a specific brand of drug, which is the goal of all direct-to-consumer pharmaceutical advertising.Not until the Internet, in the minds of pharmaceutical marketers, becomes more like TV, will the needle move on pharma Internet-based DTC advertising.Rich Media Can Change Pharma's Mind About the InternetBut guess what! The Internet is becoming much more like TV because of Rich Media, which includes streaming audio video (eg, podcasts), animations and other programs that engage viewers like TV does, but also allows them to interact with the advertisement in ways that are not possible with TV.More and more, I have seen pharmaceutical Web sites that embed videos of their latest TV ads. Some have even solicited consumer-generated videos for submission to YouTube.I've been experimenting myself with rich media -- see "Blogs are Done! What’s Next for Pharma Marketing?". My most recent endeavor in this area is what I call a Vendor Video Showcase that I introduced at my June 4, 2008 Networking Dinner Reception.For some time I have maintained an online directory of pharmaceutical vendors, solution providers, and consultants over at the Pharma Marketing Network portal (see http://www.vendors.pharma-mkting.com/).Up until now it was your typical static, Yellow pages type listing with text, maybe a graphical logo and links to the advertiser's Web site. The text included a short 150-250 word "pitch" for why pharmaceutical companies should hire the company in the listing.Very standard stuff. Not terribly engaging and it doesn't give you a feel for the people who run the company. The Vendor Video Showcase is a new and exciting promotional option for the directory that helps overcome this limitation. It features an embedded video "sales pitch" included in the listing in which a company representative -- the CEO is best -- makes a 1-minute presentation about the company and what it has to offer. To see this in action, please visit the Consultants, Management/Strategy page of the directory and listen to Jan Heybroek, President of The Arcas Group. Jan's video pitch was recorded live at the networking dinner.Aside from the video embedded in the listing, what's neat about this is that the video is also posted to my YouTube Channel where people -- eg, current and former clients of The Arcas Group -- can post comments (eg, testimonials) and rate the video. Just like pharma companies, however, advertisers may consider these "social media" aspects a double-edged sword. There is always the option to turn these functions off or to moderate comments before publishing them. The other advantage of housing the videos on YouTube is that they can be found by a Google search, which adds to the utility.
Thirteen (13) pharmaceutical companies made it into AdAge's 2008 list of 100 National Advertisers. They are:
GlaxoSmithKline
Johnson & Johnson
Pfizer
Schering-Plough Corp.
Wyeth
Bayer
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Merck & Co.
AstraZeneca
Novartis
Boehringer Ingelheim
Sanofi-AventisThe list is based on "measured media" spending across 19 media and includes estimates of "unmeasured media," which includes direct marketing, product placement, and most notably, paid Internet search, which some analysts estimate is about 40% of the total ad spend of companies in general.New to the list this year is Boehringer Ingelheim, which markets Mirapex for Restless Leg Syndrome in competition with GSK's Requip.The total spend for these 13 pharma companies in 2007 was $6,998,700,000 measured vs. and estimated $6,834,600,000 unmeasured. That represents 13.1% of the total spending in 2007 of the entire group. NOTE: Not all of this represents direct-to-consumer (DTC) advertising. Magazines, for example, include B-2-B publications (ie, medical journals focused on physicians).I plotted the media mix for pharma advertisers vs. non-pharma companies in the list and came up with this (click on the image for a larger view):Based on these data, the top spending pharma companies have a media mix distinctly different from the top non-pharma companies. Pharma devotes a greater slice of its advertising pie to TV and magazines than do non-pharma companies. In fact, 92% of pharma's budget is devoted to these two categories of media! That leaves scant dollars for other media.It makes sense that pharma would not spend as large a portion of its ad budget on newspapers, radio, and outdoor venues. These media focus on local markets rather than mass markets and pharma has little need to tailor their messages to local markets (although some drug categories may benefit from more exposure in communities with disproportionate medical problems, such as diabetes in African-American neighborhoods).Why Pharma Lags in Internet AdvertisingBut it is surprising that pharmaceutical companies -- at least the 13 in this group of top spenders -- devotes only 3.1% of their ad budgets on the Internet whereas non-pharmaceutical companies devote 7.3% of their budgets to the Internet.Why is this?I believe that most pharmaceutical marketers have a mass-market mentality and do not view the Internet as a mass market medium. Every defense I've heard from these marketers for why they are not spending much on the Internet includes the phrase "lack of reach" in comparison to TV and magazines. True enough.Also, the Internet is not nearly as motivating as TV in getting consumers to visit their doctors and ask for a specific brand of drug, which is the goal of all direct-to-consumer pharmaceutical advertising.Not until the Internet, in the minds of pharmaceutical marketers, becomes more like TV, will the needle move on pharma Internet-based DTC advertising.Rich Media Can Change Pharma's Mind About the InternetBut guess what! The Internet is becoming much more like TV because of Rich Media, which includes streaming audio video (eg, podcasts), animations and other programs that engage viewers like TV does, but also allows them to interact with the advertisement in ways that are not possible with TV.More and more, I have seen pharmaceutical Web sites that embed videos of their latest TV ads. Some have even solicited consumer-generated videos for submission to YouTube.I've been experimenting myself with rich media -- see "Blogs are Done! What’s Next for Pharma Marketing?". My most recent endeavor in this area is what I call a Vendor Video Showcase that I introduced at my June 4, 2008 Networking Dinner Reception.For some time I have maintained an online directory of pharmaceutical vendors, solution providers, and consultants over at the Pharma Marketing Network portal (see http://www.vendors.pharma-mkting.com/).Up until now it was your typical static, Yellow pages type listing with text, maybe a graphical logo and links to the advertiser's Web site. The text included a short 150-250 word "pitch" for why pharmaceutical companies should hire the company in the listing.Very standard stuff. Not terribly engaging and it doesn't give you a feel for the people who run the company. The Vendor Video Showcase is a new and exciting promotional option for the directory that helps overcome this limitation. It features an embedded video "sales pitch" included in the listing in which a company representative -- the CEO is best -- makes a 1-minute presentation about the company and what it has to offer. To see this in action, please visit the Consultants, Management/Strategy page of the directory and listen to Jan Heybroek, President of The Arcas Group. Jan's video pitch was recorded live at the networking dinner.Aside from the video embedded in the listing, what's neat about this is that the video is also posted to my YouTube Channel where people -- eg, current and former clients of The Arcas Group -- can post comments (eg, testimonials) and rate the video. Just like pharma companies, however, advertisers may consider these "social media" aspects a double-edged sword. There is always the option to turn these functions off or to moderate comments before publishing them. The other advantage of housing the videos on YouTube is that they can be found by a Google search, which adds to the utility.
Thursday, June 5, 2008
Internet Vs. Sales Reps
Internet vs. Sales Reps: Which Do Docs Prefer?
Verispan's 2007 ePromotion Annual Study estimates that "ten percent of middle customer opted for electronic detailing instead of in-person sales calls with Sales reps." One article published some other "hard to ignore" numbers from this study:
47 percent of customer feel that e-promotion is the same as face-to-face detailing
21 percent feel that feel that e-detailing is superior to live detailing
50 percent said that they would be somewhat likely to prescribe a drug they learned about through e-detail
44 percent expect to boost their e-promotion involvement in the coming yearMerck Leads the WayThe Verispan audit singles out Merck, whose spending on ePromotion activities has more than quadrupled over the last 3 years, reaching almost $83 million in 2007. In fact, Merck currently leads the industry in ePromotion investment, accounting for over 20% of industry spending for this promotional method. It appears that Merck is walking the walk as well as talking the talk when it comes to using technology to improve marketing and sales ROI (see "Merck Rejiggers Its Marketing Mix: Will Other Pharma Companies Follow?").Verispan defines ePromotion as video details, online events and virtual details. It's all about product information. But what about other information of interest or value to physicians that is not all about the brand?TNS Healthcare is interested in what drives physicians to be loyal to a drug brand (see, for example, "Reinventing the Sales Model"). They have found, for example, that US primary care physicians value physician education and information services provided by pharmaceutical companies as much as the quality of sales reps' visits (66% vs. 68% of physicians surveyed value the former vs. the latter, respectively).Internet vs. Sales RepsBut how valuable is the Internet as a source of this information vs. sales reps? TNS surveyed physicians in 6 countries (US, UK, France, Germany, Spain, and Italy) to find the answer to this and other questions.The survey showed a wide variation in the value that primary care physicians place on the Internet vs. pharma sales reps as a source of education and information services (see chart, click for an enlarged view).In the US, Internet services, while not as popular among physicians as other aspects of the relationship, did show a move to be valued by more physicians in 2008 vs. 2007 (42% vs. 37%, respectively)."Given the amount of attention and spending devoted to Internet services generally, it is surprising that the Internet does not represent an area of greater physician demand," said Jonathan Kay, President, Portfolio, TNS Healthcare. He made his comments during a recent webinar.
Verispan's 2007 ePromotion Annual Study estimates that "ten percent of middle customer opted for electronic detailing instead of in-person sales calls with Sales reps." One article published some other "hard to ignore" numbers from this study:
47 percent of customer feel that e-promotion is the same as face-to-face detailing
21 percent feel that feel that e-detailing is superior to live detailing
50 percent said that they would be somewhat likely to prescribe a drug they learned about through e-detail
44 percent expect to boost their e-promotion involvement in the coming yearMerck Leads the WayThe Verispan audit singles out Merck, whose spending on ePromotion activities has more than quadrupled over the last 3 years, reaching almost $83 million in 2007. In fact, Merck currently leads the industry in ePromotion investment, accounting for over 20% of industry spending for this promotional method. It appears that Merck is walking the walk as well as talking the talk when it comes to using technology to improve marketing and sales ROI (see "Merck Rejiggers Its Marketing Mix: Will Other Pharma Companies Follow?").Verispan defines ePromotion as video details, online events and virtual details. It's all about product information. But what about other information of interest or value to physicians that is not all about the brand?TNS Healthcare is interested in what drives physicians to be loyal to a drug brand (see, for example, "Reinventing the Sales Model"). They have found, for example, that US primary care physicians value physician education and information services provided by pharmaceutical companies as much as the quality of sales reps' visits (66% vs. 68% of physicians surveyed value the former vs. the latter, respectively).Internet vs. Sales RepsBut how valuable is the Internet as a source of this information vs. sales reps? TNS surveyed physicians in 6 countries (US, UK, France, Germany, Spain, and Italy) to find the answer to this and other questions.The survey showed a wide variation in the value that primary care physicians place on the Internet vs. pharma sales reps as a source of education and information services (see chart, click for an enlarged view).In the US, Internet services, while not as popular among physicians as other aspects of the relationship, did show a move to be valued by more physicians in 2008 vs. 2007 (42% vs. 37%, respectively)."Given the amount of attention and spending devoted to Internet services generally, it is surprising that the Internet does not represent an area of greater physician demand," said Jonathan Kay, President, Portfolio, TNS Healthcare. He made his comments during a recent webinar.
Monday, May 26, 2008
FT IR Spectroscopy market in India
FTIR market and the products available in India:-
FTIR and NIR markets are very diverse in terms of its utilization hence they are sold in the specific applications that the instrumentation performs. These can be classified as routine or non-routine instruments.
Routine: The instruments are used for day-to-day performance with a fixed task, identification, quantification, in process or final materials, in academics teaching etc.
Non-routine: The instruments which are used for trouble shooting and research and development purpose, spectroscopic evaluations, product development where the utility of FTIR or NIR will vary as per the purpose.
The FT-NIR analyzers market has several vendors and specific technologies. The market in India has been growing for last few years and around 250 units ($9 million) of IR and NIR products have been sold.
Infra-red market is growing in India. FTIR is well established and Near-IR is getting accepted in the Process Analytical Technology (PAT). However, Indian market is price sensitive. There are plenty of opportunities in routine as well as non-routine market with the involvement of hyphenated techniques such as IR-Microscopy Imaging, TG-IR, Optical measurements and Chemometrics.
FT IR market growth in India is around 12 – 15% per annum.
Regard
Bhausaheb Sasawade
Business Development Exicutive
MDML
Hyderabad
09701711103
FTIR and NIR markets are very diverse in terms of its utilization hence they are sold in the specific applications that the instrumentation performs. These can be classified as routine or non-routine instruments.
Routine: The instruments are used for day-to-day performance with a fixed task, identification, quantification, in process or final materials, in academics teaching etc.
Non-routine: The instruments which are used for trouble shooting and research and development purpose, spectroscopic evaluations, product development where the utility of FTIR or NIR will vary as per the purpose.
The FT-NIR analyzers market has several vendors and specific technologies. The market in India has been growing for last few years and around 250 units ($9 million) of IR and NIR products have been sold.
Infra-red market is growing in India. FTIR is well established and Near-IR is getting accepted in the Process Analytical Technology (PAT). However, Indian market is price sensitive. There are plenty of opportunities in routine as well as non-routine market with the involvement of hyphenated techniques such as IR-Microscopy Imaging, TG-IR, Optical measurements and Chemometrics.
FT IR market growth in India is around 12 – 15% per annum.
Regard
Bhausaheb Sasawade
Business Development Exicutive
MDML
Hyderabad
09701711103
Wednesday, May 21, 2008
marketing of Bio-instrument
I am fresher in this field.. but Bio-instrument marketing is upcoming field ....
Subscribe to:
Comments (Atom)
